CA2138998A1 - Methods and compositions for treating depression and other disorders using optically pure(-) sibutramine - Google Patents

Methods and compositions for treating depression and other disorders using optically pure(-) sibutramine

Info

Publication number
CA2138998A1
CA2138998A1 CA002138998A CA2138998A CA2138998A1 CA 2138998 A1 CA2138998 A1 CA 2138998A1 CA 002138998 A CA002138998 A CA 002138998A CA 2138998 A CA2138998 A CA 2138998A CA 2138998 A1 CA2138998 A1 CA 2138998A1
Authority
CA
Canada
Prior art keywords
sibutramine
amount
pharmaceutically acceptable
human
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002138998A
Other languages
English (en)
French (fr)
Inventor
James W. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2138998A1 publication Critical patent/CA2138998A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002138998A 1992-06-23 1993-06-22 Methods and compositions for treating depression and other disorders using optically pure(-) sibutramine Abandoned CA2138998A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90304092A 1992-06-23 1992-06-23
US903,040 1992-06-23

Publications (1)

Publication Number Publication Date
CA2138998A1 true CA2138998A1 (en) 1994-01-06

Family

ID=25416838

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002138998A Abandoned CA2138998A1 (en) 1992-06-23 1993-06-22 Methods and compositions for treating depression and other disorders using optically pure(-) sibutramine

Country Status (5)

Country Link
EP (1) EP0647134A4 (de)
JP (1) JPH08500093A (de)
AU (1) AU4542893A (de)
CA (1) CA2138998A1 (de)
WO (1) WO1994000114A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006963A1 (en) * 1992-06-23 2002-01-17 Young James W. Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
GB9402641D0 (en) * 1994-02-11 1994-04-06 Boots Co Plc Therapeutic agents
US5676967A (en) * 1995-04-18 1997-10-14 Brennen Medical, Inc. Mesh matrix wound dressing
DE19518988A1 (de) * 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6197828B1 (en) 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6323242B1 (en) * 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
MXPA01009461A (es) * 1999-03-19 2004-03-19 Abbott Gmbh & Co Kg Tratamiento de osteoartritis.
CA2368083A1 (en) 1999-04-06 2000-10-12 Sepracor Inc. Derivatives of venlafaxine and methods of preparing and using the same
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US20020115727A1 (en) * 2000-12-04 2002-08-22 Senanayake Chris H. Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
DK1360169T3 (da) 2001-02-12 2007-11-26 Wyeth Corp Succinatsalt af O-desmethyl-venlafaxin
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
EP1499309A4 (de) * 2002-04-24 2008-05-28 Cypress Bioscience Inc Prävention und behandlung von funktionellen somatischen erkrankungen, einschliesslich stressbedingten erkrankungen
CA2493490A1 (en) * 2002-07-24 2004-01-29 Cypress Bioscience, Inc. Treatment of depression secondary to pain (dsp)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3008993A1 (de) * 1980-03-08 1981-10-01 Röhm Pharma GmbH, 6100 Darmstadt Pharmazeutische zubereitungen
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5104899A (en) * 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine

Also Published As

Publication number Publication date
WO1994000114A1 (en) 1994-01-06
AU4542893A (en) 1994-01-24
JPH08500093A (ja) 1996-01-09
EP0647134A1 (de) 1995-04-12
EP0647134A4 (de) 1997-07-30

Similar Documents

Publication Publication Date Title
CA2138998A1 (en) Methods and compositions for treating depression and other disorders using optically pure(-) sibutramine
US6110973A (en) Methods for treating obesity and weight gain using optically pure (-)-bupropion
CA2139000A1 (en) Methods and compositions for treating depression and other disorders using optically pure(+) sibutramine
US5648396A (en) Methods for treating depression and other disorders using optically pure R (-) fluoxetine and monoamine oxidase inhibitor
TWI298255B (en) Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder
JP2013256526A (ja) （−）−ベンラファキシン誘導体並びにその製造方法および使用方法
JP2003501344A (ja) （＋）−ベンラファキシン誘導体並びにその製造方法および使用方法
EP1904066B1 (de) KOMBINATIONEN VON ESZOPICLON UND TRANS-4-(3,4-DICHLORPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE OR TRANS-4-(3,4-DICHLORPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALINAMIN ZUR BEHANDLUNG DER MENOPAUSE, Perimenopause UND VON KOGNITIVEN STÖRUNGEN
US20020006964A1 (en) Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
JP2003521470A (ja) ベンラファキシンの誘導体とその調製および使用方法
EP0687472A2 (de) Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
JPH03294248A (ja) Ｎ−プロパルギル−１−アミノインダン化合物のｒ（＋）−鏡像体、それらの製造法およびそれらを含有する薬剤組成物
MX2008000249A (es) Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos.
DE69607904T2 (de) Potenzierung von Serotonin-Wirkstoffresponz
US4690949A (en) Therapeutic drug for dementia
CA2318960A1 (en) Pharmaceutical uses of optically pure (+)-bupropion
JP2004501130A (ja) ５−ｈｔ３受容体及び神経細胞のニコチン性受容体に対するアンタゴニストとしての１−アミノ−アルキルシクロヘキサン
US20020006963A1 (en) Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
AU721924B2 (en) Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
US5492933A (en) Methods and compositions for treating urinary incontinence and other disorders using optically pure R-terodiline and hydroxylated derivatives thereof
WO1992013452A1 (en) Methods of use and compositions of r(-) fluoxetine
WO1995010270A1 (en) Method for treating urinary incontinence using optically pure s-terodiline

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20050622